Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | PTGES | O14684 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CA3 | P07451 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502699 | 0.85 | PTGS2 (0.66) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6912425 | 0.85 | PTGS2 (0.66) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6450305 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6721381 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL15409313 | 0.80 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6600273 | 0.80 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3669597 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3708 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6721625 | 0.79 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL9998656 | 0.78 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656641-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250186472-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | Neonc Technologies, Inc. | 2025-06-12 | — | — | US | claimed |
| US-20240239730-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-07-18 | — | — | US | claimed |
| US-11970436-B2 | Pharmaceutical compositions comprising monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-04-30 | — | — | US | claimed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | claimed |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. | 2023-12-21 | — | — | US | claimed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | claimed |
| EP-4243794-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| EP-4228648-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | Neonc Technologies, Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| CN-116615197-A | Treatment of recurrent glioblastoma with perillyl alcohol | NeOnc技术股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-103168018-A | Pharmaceutical composition comprising POH derivative | NEONC TECHNOLOGIES INC | 2013-06-19 | — | — | CN | claimed |
| EP-2542082-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | Neonc Technologies Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-20120219541-A1 | Therapeutic Compositions Comprising Monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA | 2012-08-30 | — | — | US | claimed |
| US-8236862-B2 | Therapeutic compositions comprising monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-08-07 | — | — | US | claimed |
| CN-102405044-A | Therapeutic compositions containing monoterpenes | UNIV SOUTHERN CALIFORNIA | 2012-04-04 | — | — | CN | claimed |
| EP-2393488-A1 | THERAPEUTIC COMPOSITIONS COMPRISING MONOTERPENES | University Of Southern California (US) | 2011-12-14 | — | — | EP | claimed |
| US-20110280860-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | NEONC TECHNOLOGIES INC. | 2011-11-17 | — | — | US | claimed |
| WO-2011109635-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | NEONC TECHNOLOGIES INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20100226913-A1 | Therapeutic Compositions Comprising Monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-09-09 | — | — | US | claimed |
| WO-2010091198-A1 | THERAPEUTIC COMPOSITIONS COMPRISING MONOTERPENES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239730-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | SQLE, DHPS, GGPS1 | PTGS2 542/4885PTGS1 761/4885PDPK1 632/4885 |
| US-20250186472-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | CFH, AQP4, MAG | PTGS2 495/4885PTGS1 518/4885PDPK1 1971/4885 |
| US-20110280860-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | SQLE, DHPS, GGPS1 | PTGS2 542/4885PTGS1 761/4885PDPK1 632/4885 |
| US-11970436-B2 | Pharmaceutical compositions comprising monoterpenes | SQLE, DHPS, GGPS1 | PTGS2 542/4885PTGS1 761/4885PDPK1 632/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PTGS2 754/4885PTGS1 787/4885PDPK1 3479/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | PTGS2 754/4885PTGS1 787/4885PDPK1 3479/4885 |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | IDH3A, IDH1, IDH3B | PTGS2 1517/4885PTGS1 1644/4885PDPK1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.